Nurix Therapeutics, Inc.
NRIX · NASDAQ
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$86,421 | -$43,464 | -$56,351 | -$58,549 |
| Dep. & Amort. | $5,000 | $5,097 | $4,128 | $4,303 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $9,772 | $10,385 | $8,722 | $8,508 |
| Change in WC | $16,461 | -$32,478 | -$14,029 | $449 |
| Other Non-Cash | -$2,197 | -$2,701 | -$3,557 | -$3,462 |
| Operating Cash Flow | -$57,385 | -$63,161 | -$61,087 | -$48,751 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$2,711 | -$2,675 | -$3,485 | -$2,105 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$102,999 | -$68,168 | -$110,183 | -$298,215 |
| Inv. Sales/Matur. | $156,185 | $142,342 | $139,201 | $159,503 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | $50,475 | $71,499 | $25,533 | -$140,817 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $1,155 | $6 | $1,473 | $199,072 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | $0 | $0 | $1,449 |
| Financing Cash Flow | $1,155 | $6 | $1,473 | $200,521 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$5,755 | $8,344 | -$34,081 | $10,953 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $85,161 | $76,817 | $110,898 | $99,945 |
| End Cash | $79,406 | $85,161 | $76,817 | $110,898 |
| Free Cash Flow | -$60,096 | -$65,836 | -$64,572 | -$50,856 |